Amir Hefni, Resolution Therapeutics CEO
October 3, 2024 02:30 AM EDTUpdated 06:40 AM
Financing
Cell/Gene Tx

Res­o­lu­tion rais­es $85M to test macrophage ther­a­pies in end-stage liv­er dis­ease

Ryan Cross

Senior Science Correspondent

By the end of the year, a British biotech plans to start test­ing a new kind of cell ther­a­py based on macrophages, a roam­ing im­mune …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times